Implantable Tibial Neuromodulation for Overactive Bladder
(TITAN 2 Trial)
Trial Summary
What is the purpose of this trial?
The purpose of this prospective, multicenter study is to assess the safety and efficacy of tibial neuromodulation using the Medtronic Tibial Neuromodulation (TNM) system.
Research Team
Anne Miller
Principal Investigator
Medtronic
Eligibility Criteria
This trial is for adults who've had an overactive bladder (UUI) for at least 6 months and haven't seen improvement with standard treatments. Participants must be able to follow the study's procedures, like filling out diaries and operating the device. Pregnant women, those planning pregnancy, or individuals with recent pelvic surgeries or certain anatomical issues can't join.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive tibial neuromodulation using the Medtronic TNM system
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Tibial Neuromodulation using the Medtronic Tibial Neuromodulation (TNM) system
Find a Clinic Near You
Who Is Running the Clinical Trial?
MedtronicNeuro
Lead Sponsor
Geoff Martha
MedtronicNeuro
Chief Executive Officer since 2020
Finance degree from Penn State University
Dr. Eric Peterson
MedtronicNeuro
Chief Medical Officer since 2020
MD from University of Miami